Literature DB >> 7731726

Characterization of MEK1 phosphorylation by the v-Mos protein.

C D Pham1, R B Arlinghaus, C F Zheng, K L Guan, B Singh.   

Abstract

Activation of MAP kinase/Erk Kinase (MEK) via direct phosphorylation by Mos may be crucial for cellular transformation by the activated c-mos or v-mos gene. Recent studies on a number of different protein kinases showed that phosphorylation within a subdomain of the catalytic domain may represent a common mode of activation. In this regard, activation of MEK1 by Raf involves phosphorylation of serine residues 218 and 222. Here we show that recombinant kinase-inactive MEK1 is phosphorylated by v-Mos with equal efficiency at both Ser 218 and Ser 222 in vitro. Tryptic phosphopeptide analysis of glutathione-S-transferase (GST)-MEK1 K97R and its alanine-for-serine mutants indicated that Ser 222 is the preferred phosphorylation site. Wild-type GST-MEK1 was phosphorylated at the same sites but contained a significantly lower amount of doubly phosphorylated species then its K97R kinase-inactive mutant. The ratio of GST-MEK1 species phosphorylated at two serines to those phosphorylated at one serine was similar in auto-phosphorylated and v-Mos-phosphorylated GST-MEK1. Consistent with the in vitro data, phosphopeptide mapping of MEK1 immunoprecipitated from mos transformed cells showed an increased amount of singly phosphorylated phosphopeptide compared to nontransformed cels. MEK1 was found to be more highly activated in NIH3T3 cells transformed by an activated c-mos or v-mos gene than in cells growing normally in medium containing serum. Our data indicate that Mos activated MEK1 in vitro as well as in vivo by phosphorylating Ser 222.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731726

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Spatial phosphoprotein profiling reveals a compartmentalized extracellular signal-regulated kinase switch governing neurite growth and retraction.

Authors:  Yingchun Wang; Feng Yang; Yi Fu; Xiahe Huang; Wei Wang; Xinning Jiang; Marina A Gritsenko; Rui Zhao; Matthew E Monore; Olivier C Pertz; Samuel O Purvine; Daniel J Orton; Jon M Jacobs; David G Camp; Richard D Smith; Richard L Klemke
Journal:  J Biol Chem       Date:  2011-03-28       Impact factor: 5.157

Review 2.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

3.  Inhibition of v-Mos kinase activity by protein kinase A.

Authors:  Y Yang; C H Herrmann; R B Arlinghaus; B Singh
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

4.  Mos positively regulates Xe-Wee1 to lengthen the first mitotic cell cycle of Xenopus.

Authors:  M S Murakami; T D Copeland; G F Vande Woude
Journal:  Genes Dev       Date:  1999-03-01       Impact factor: 11.361

5.  Dependence of Mos-induced Cdc2 activation on MAP kinase function in a cell-free system.

Authors:  C Y Huang; J E Ferrell
Journal:  EMBO J       Date:  1996-05-01       Impact factor: 11.598

6.  Evidence for a potential tumor suppressor role for the Na,K-ATPase beta1-subunit.

Authors:  L J Inge; S A Rajasekaran; K Yoshimoto; P S Mischel; W McBride; E Landaw; A K Rajasekaran
Journal:  Histol Histopathol       Date:  2008-04       Impact factor: 2.303

7.  Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects.

Authors:  Kyle P Smith; Kathleen M Gifford; Joshua S Waitzman; Sarah E Rice
Journal:  Proteins       Date:  2014-11-18

8.  Evidence of an interaction between Mos and Hsp70: a role of the Mos residue serine 3 in mediating Hsp70 association.

Authors:  H Liu; V B Vuyyuru; C D Pham; Y Yang; B Singh
Journal:  Oncogene       Date:  1999-06-10       Impact factor: 9.867

9.  Mos in the oocyte: how to use MAPK independently of growth factors and transcription to control meiotic divisions.

Authors:  Aude Dupré; Olivier Haccard; Catherine Jessus
Journal:  J Signal Transduct       Date:  2010-12-19

10.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.

Authors:  Cory M Johannessen; Laura A Johnson; Federica Piccioni; Aisha Townes; Dennie T Frederick; Melanie K Donahue; Rajiv Narayan; Keith T Flaherty; Jennifer A Wargo; David E Root; Levi A Garraway
Journal:  Nature       Date:  2013-11-03       Impact factor: 49.962

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.